Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Market Cap
$1.05B
P/E Ratio
-3.82
1Y Stock Return
14.51%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
5.1
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Current Value
$9.451 Year Return
Current Value
$9.451 Year Return
Finnhub
WALTHAM, BOULDER - Cogent Biosciences, Inc. , a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and...
Finnhub
Top-line results from registration-directed SUMMIT, PEAK and APEX trials expected in 2025 Phase 1 trial initiated for CGT-4859, a reversible, potent, selective, FGFR2 inhibitor SUMMIT...
Finnhub
WALTHAM, BOULDER - Cogent Biosciences, Inc. , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two presentations featuring...
Yahoo
Company to host webcast on December 9, 2024 at 8:00am ET/5:00am PTWALTHAM, Mass. and BOULDER, Colo., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two presentations featuring bezuclastinib at the 66th Annual Meeting of the American Society of Hematology (ASH) being held December 7-10, 2024 in San Diego, California. The first presentation will describe l
Yahoo
Preclinical data highlight company’s fourth discovery stage program, a novel potent and selective KRAS(ON) inhibitor Updated preclinical data from CGT6297, Cogent’s H1047R mutant-selective PI3Kα inhibitor demonstrates robust inhibition of downstream signaling and efficacy WALTHAM, Mass. and BOULDER, Colo., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced t
Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GDDY | 0.05% | $27.74B | +91.49% | 0.00% |
AZO | 0.07% | $53.75B | +19.35% | 0.00% |
ORN | 0.09% | $336.11M | +84.62% | 0.00% |
POAI | 0.10% | $5.48M | -75.00% | 0.00% |
RGA | -0.10% | $14.98B | +38.69% | 1.52% |
NAT | -0.13% | $551.22M | -33.83% | 15.82% |
CAR | -0.14% | $3.72B | -42.35% | 0.00% |
FTNT | -0.15% | $73.06B | +82.43% | 0.00% |
RBRK | 0.17% | $8.98B | +54.47% | 0.00% |
XBIT | 0.21% | $217.96M | +81.93% | 0.00% |
OR | -0.21% | $3.57B | +34.22% | 0.96% |
ETON | -0.21% | $321.92M | +240.44% | 0.00% |
CANG | -0.21% | $340.41M | +347.62% | 0.00% |
LTM | 0.24% | $8.40B | -100.00% | <0.01% |
GO | -0.28% | $1.94B | -31.48% | 0.00% |
TMUS | -0.28% | $284.11B | +60.22% | 1.15% |
ATMU | -0.31% | $3.63B | +89.33% | 0.23% |
LBRT | -0.32% | $3.03B | -6.59% | 1.49% |
TK | -0.34% | $674.08M | +6.84% | 0.00% |
BLX | 0.34% | $1.25B | +39.30% | 5.80% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HCSG | 49.98% | $913.21M | +23.49% | 0.00% |
KROS | 37.94% | $2.30B | +78.23% | 0.00% |
KTOS | 37.86% | $4.07B | +33.09% | 0.00% |
GLDD | 33.87% | $842.25M | +74.86% | 0.00% |
VPG | 32.76% | $312.43M | -24.14% | 0.00% |
BFAM | 32.53% | $6.72B | +25.75% | 0.00% |
MRC | 31.94% | $1.20B | +33.24% | 0.00% |
ALDX | 30.32% | $287.03M | +47.40% | 0.00% |
GIL | 30.19% | $7.74B | +34.42% | 1.63% |
LAW | 29.95% | $359.45M | -6.10% | 0.00% |
MQ | 29.79% | $1.96B | -37.90% | 0.00% |
BLNK | 29.69% | $163.90M | -49.69% | 0.00% |
OMER | 29.37% | $692.50M | +370.47% | 0.00% |
ALLO | 29.00% | $534.66M | -0.39% | 0.00% |
ALT | 28.82% | $629.45M | +91.14% | 0.00% |
EDIT | 28.73% | $180.78M | -80.18% | 0.00% |
IREN | 28.18% | $2.38B | +134.57% | 0.00% |
CLFD | 28.16% | $446.80M | +19.63% | 0.00% |
PGEN | 27.98% | $266.19M | -25.50% | 0.00% |
GHM | 27.82% | $488.30M | +136.62% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CI | -26.73% | $93.75B | +28.20% | 1.61% |
QDEL | -26.26% | $2.75B | -40.43% | 0.00% |
RDDT | -14.32% | $24.87B | +316.59% | 0.00% |
M | -12.59% | $4.70B | -3.15% | 4.08% |
ALAB | -12.16% | $16.40B | +187.19% | 0.00% |
LITB | -12.13% | $33.46M | -74.29% | 0.00% |
MCK | -12.03% | $78.87B | +35.27% | 0.43% |
KHC | -11.78% | $38.22B | -11.75% | 5.06% |
DOCU | -11.71% | $16.29B | +74.93% | 0.00% |
AKAM | -11.27% | $14.71B | -15.50% | 0.00% |
ADBE | -10.00% | $227.23B | -14.62% | 0.00% |
COR | -9.99% | $48.29B | +22.63% | 0.82% |
SEG | -9.91% | $395.76M | +20.95% | 0.00% |
CAH | -9.81% | $29.64B | +13.97% | 1.63% |
CMG | -9.77% | $82.49B | +36.40% | 0.00% |
R | -9.55% | $7.19B | +56.55% | 1.79% |
KDP | -9.13% | $44.14B | +0.96% | 2.70% |
CAE | -9.12% | $7.52B | +15.30% | 0.00% |
LMT | -7.98% | $123.34B | +15.45% | 2.45% |
SMC | -7.49% | $403.37M | +96.68% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SMB | -0.03% | $268.43M | 0.07% |
BCD | 0.07% | $243.18M | 0.3% |
FMF | 0.18% | $248.49M | 0.95% |
WEAT | -0.46% | $119.27M | 0.28% |
KCCA | -0.67% | $219.07M | 0.87% |
CSHI | 0.67% | $493.76M | 0.38% |
BCI | 0.71% | $1.21B | 0.26% |
TBIL | 0.80% | $4.42B | 0.15% |
IYK | 0.93% | $1.35B | 0.4% |
IBDP | 1.18% | $2.03B | 0.1% |
CMDY | 1.36% | $284.26M | 0.28% |
FTXG | 1.56% | $31.94M | 0.6% |
JUCY | -1.99% | $325.86M | 0.6% |
GBIL | 2.04% | $5.68B | 0.12% |
JBBB | -2.13% | $1.35B | 0.49% |
FLRT | -2.14% | $413.80M | 0.6% |
BILZ | 2.31% | $541.42M | 0.14% |
CLOI | 2.36% | $749.05M | 0.4% |
HDRO | -2.51% | $164.26M | 0.3% |
DBMF | -2.62% | $1.04B | 0.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 36.90% | $7.29B | 0.35% |
GNOM | 36.16% | $79.38M | 0.5% |
PTH | 33.60% | $141.39M | 0.6% |
EFAA | 33.54% | $105.52M | 0% |
RSPA | 32.92% | $278.68M | 0% |
ARKG | 32.69% | $1.27B | 0.75% |
KOMP | 31.90% | $2.22B | 0.2% |
SATO | 31.70% | $11.71M | 0.6% |
IBB | 31.12% | $6.97B | 0.45% |
IWC | 30.70% | $996.57M | 0.6% |
QQA | 30.68% | $140.88M | 0% |
DAPP | 29.85% | $204.11M | 0.51% |
PBE | 29.57% | $263.25M | 0.58% |
QCLN | 29.34% | $611.59M | 0.59% |
BLOK | 29.32% | $933.23M | 0.76% |
BITQ | 29.18% | $215.94M | 0.85% |
IWO | 28.56% | $13.37B | 0.24% |
PBD | 28.45% | $90.38M | 0.75% |
ARKK | 28.35% | $6.76B | 0.75% |
XPH | 28.29% | $164.49M | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -23.12% | $365.42M | 1.43% |
BSCO | -12.91% | $2.27B | 0.1% |
VIXY | -11.58% | $195.31M | 0.85% |
USDU | -11.38% | $210.52M | 0.5% |
KMLM | -11.17% | $344.74M | 0.9% |
UUP | -11.02% | $376.91M | 0.77% |
DBO | -10.76% | $218.47M | 0.77% |
SOYB | -10.68% | $27.06M | 0.22% |
USCI | -10.39% | $188.19M | 1.07% |
DBE | -10.31% | $50.22M | 0.77% |
MINT | -10.03% | $11.69B | 0.35% |
PREF | -9.95% | $1.02B | 0.55% |
AGZD | -9.86% | $132.76M | 0.23% |
TPMN | -9.58% | $40.42M | 0.65% |
EQLS | -9.27% | $8.93M | 1% |
COMT | -5.97% | $839.86M | 0.48% |
CORN | -5.54% | $59.94M | 0.2% |
DBA | -5.45% | $787.55M | 0.93% |
GSG | -5.08% | $932.06M | 0.75% |
PDBC | -4.25% | $4.39B | 0.59% |